DexCom, Inc. (NASDAQ:DXCM – Get Free Report) Director Mark Foletta sold 4,000 shares of DexCom stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $74.13, for a total transaction of $296,520.00. Following the completion of the transaction, the director directly owned 52,852 shares in the company, valued at approximately $3,917,918.76. The trade was a 7.04% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
DexCom Stock Down 2.6%
NASDAQ:DXCM traded down $1.93 during midday trading on Wednesday, reaching $71.23. 4,301,255 shares of the stock traded hands, compared to its average volume of 5,344,921. The stock has a market capitalization of $27.49 billion, a PE ratio of 30.44, a price-to-earnings-growth ratio of 1.16 and a beta of 1.45. DexCom, Inc. has a 12-month low of $54.11 and a 12-month high of $89.98. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.64 and a current ratio of 1.95. The business has a 50-day moving average of $66.59 and a two-hundred day moving average of $67.76.
DexCom (NASDAQ:DXCM – Get Free Report) last issued its quarterly earnings results on Thursday, April 30th. The medical device company reported $0.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.47 by $0.09. DexCom had a return on equity of 33.33% and a net margin of 19.31%.The business had revenue of $1.19 billion for the quarter, compared to the consensus estimate of $1.17 billion. During the same period in the prior year, the firm posted $0.32 earnings per share. The business’s quarterly revenue was up 15.0% on a year-over-year basis. On average, equities analysts forecast that DexCom, Inc. will post 2.58 earnings per share for the current fiscal year.
Analyst Ratings Changes
Read Our Latest Analysis on DexCom
Institutional Inflows and Outflows
Hedge funds have recently modified their holdings of the company. Gradient Investments LLC boosted its position in DexCom by 13.8% in the fourth quarter. Gradient Investments LLC now owns 332,006 shares of the medical device company’s stock valued at $22,035,000 after buying an additional 40,343 shares during the last quarter. Nordea Investment Management AB raised its position in DexCom by 118.6% during the 4th quarter. Nordea Investment Management AB now owns 254,315 shares of the medical device company’s stock worth $16,988,000 after buying an additional 137,986 shares during the last quarter. NEOS Investment Management LLC lifted its stake in DexCom by 58.7% during the 3rd quarter. NEOS Investment Management LLC now owns 175,982 shares of the medical device company’s stock valued at $11,842,000 after acquiring an additional 65,066 shares during the period. Banco Santander S.A. lifted its stake in DexCom by 28.9% during the 3rd quarter. Banco Santander S.A. now owns 250,310 shares of the medical device company’s stock valued at $16,843,000 after acquiring an additional 56,062 shares during the period. Finally, Banque Pictet & Cie SA boosted its holdings in shares of DexCom by 58.2% in the 4th quarter. Banque Pictet & Cie SA now owns 109,823 shares of the medical device company’s stock valued at $7,289,000 after acquiring an additional 40,411 shares during the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.
About DexCom
DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.
Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.
See Also
- Five stocks we like better than DexCom
- Cheap Thrills: Why These 3 Entertainment Stocks Are Soaring
- CoreWeave Insider Sales Look Big, But Should Investors Worry?
- Critical Metals: Sizing Up This Tiny Rare-Earth Stock Making Big Moves
- Meta and Cloud Computing: Real Potential, or a Shot in the Dark?
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.
